These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 1418864)

  • 1. Effect of the selective MAO-A inhibitors brofaromine, clorgyline and moclobemide on human platelet MAO-B activity.
    Gleiter CH; Nilsson E; Mühlbauer B; Antonin KH; Bieck PR
    J Neural Transm Gen Sect; 1992; 89(1-2):129-33. PubMed ID: 1418864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine.
    Lavian G; Finberg JP; Youdim MB
    Clin Neuropharmacol; 1993; 16 Suppl 2():S1-7. PubMed ID: 8313392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of moclobemide on rat brain monoamine oxidase A and B: comparison with harmaline and clorgyline.
    Gerardy J
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):793-802. PubMed ID: 7938567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors.
    Da Prada M; Kettler R; Keller HH; Burkard WP; Haefely WE
    J Neural Transm Suppl; 1989; 28():5-20. PubMed ID: 2677242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of [3H]brofaromine to monoamine oxidase A in vivo: displacement by clorgyline and moclobemide.
    Waldmeier PC; Stöcklin K
    Eur J Pharmacol; 1990 May; 180(2-3):297-304. PubMed ID: 2365007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors.
    Bieck PR; Antonin KH
    J Neural Transm Suppl; 1989; 28():21-31. PubMed ID: 2794993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of 5-HT-induced anorexia: a test of the reversibility of monoamine oxidase inhibitors.
    Fletcher PJ; Yu PH
    Psychopharmacology (Berl); 1989; 98(2):265-8. PubMed ID: 2502797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats.
    Kettler R; Da Prada M; Burkard WP
    Acta Psychiatr Scand Suppl; 1990; 360():101-2. PubMed ID: 2248058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of neurochemical effects of the monoamine oxidase inhibitors phenelzine, moclobemide and brofaromine in the rat after short- and long-term administration.
    Urichuk LJ; Allison K; Holt A; Greenshaw AJ; Baker GB
    J Affect Disord; 2000 May; 58(2):135-44. PubMed ID: 10781703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of reversible and selective inhibitors of monoamine oxidase type A.
    Finberg JP
    Acta Psychiatr Scand Suppl; 1995; 386():8-13. PubMed ID: 7717096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoamine oxidase inhibition by the MAO-A inhibitors brofaromine and clorgyline in healthy volunteers.
    Gleiter CH; Mühlbauer B; Schulz RM; Nilsson E; Antonin KH; Bieck PR
    J Neural Transm Gen Sect; 1994; 95(3):241-5. PubMed ID: 7865179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does moclobemide stimulate melatonin synthesis as the other selective MAO-A inhibitors do?
    Oxenkrug GF; Requintina PJ; Yuwiler A
    J Neural Transm Suppl; 1990; 32():171-5. PubMed ID: 2089086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man.
    Bitsios P; Langley RW; Tavernor S; Pyykkö K; Scheinin M; Szabadi E; Bradshaw CM
    Br J Clin Pharmacol; 1998 Jun; 45(6):551-8. PubMed ID: 9663810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of the new MAO-A inhibitors moclobemide, brofaromine and toloxatone with tranylcypromine in an animal experiment: significance for clinical practice].
    Da Prada M; Keller HH; Kettler R
    Psychiatr Prax; 1989 Aug; 16 Suppl 1():18-24. PubMed ID: 2587673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition.
    Kan JP; Steinberg R; Mouget-Goniot C; Worms P; Bizière K
    J Pharmacol Exp Ther; 1987 Jan; 240(1):251-8. PubMed ID: 3100771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic effect of the irreversible and reversible selective MAO-A inhibitors on rat pineal melatonin biosynthesis.
    Oxenkrug GF; Requintina PJ; McIntyre IM; White K
    J Neural Transm Suppl; 1994; 41():381-4. PubMed ID: 7523585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites.
    Wiesel FA; Raaflaub J; Kettler R
    Eur J Clin Pharmacol; 1985; 28(1):89-95. PubMed ID: 3987791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiosynthesis of [11C]brofaromine, a potential tracer for imaging monoamine oxidase A.
    Ametamey SM; Beer HF; Guenther I; Antonini A; Leenders KL; Waldmeier PC; Schubiger PA
    Nucl Med Biol; 1996 Apr; 23(3):229-34. PubMed ID: 8782230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of phenelzine and other monoamine oxidase inhibitor antidepressants on brain and liver I2 imidazoline-preferring receptors.
    Alemany R; Olmos G; García-Sevilla JA
    Br J Pharmacol; 1995 Feb; 114(4):837-45. PubMed ID: 7773544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hypertensive crises with reversible inhibitors of monoamine oxidases? Results of tyramine interaction studies].
    Bieck PR
    Psychiatr Prax; 1989 Aug; 16 Suppl 1():25-31. PubMed ID: 2587674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.